Resivant Medical Advances Cutiva PLUS in First Human Use

AKRON, Ohio, August 18, 2026

Cutiva PLUS Reaches First Human Clinical Use

The first patient procedures were performed on June 22 and June 23, 2026, by David Friscia, MD, an orthopaedic foot and ankle surgeon at Eisenhower Health in Rancho Mirage, California. According to Resivant Medical, all cases proceeded without complication. The company describes the achievement as the first clinical use of its proprietary Cutiva siliconized adhesive platform and a significant milestone in the development of a new cyanoacrylate chemistry for topical skin closure. The technology is intended to provide strong wound closure while improving flexibility, durability and patient comfort. Resivant said the milestone follows the successful transfer of its proprietary adhesive chemistry to commercial-scale manufacturing, allowing the company to begin clinical use while continuing to expand production capacity in preparation for a broader market launch.

New Adhesive Chemistry Combines Strength and Flexibility

The Cutiva™ PLUS Skin Closure System combines a high-viscosity, no-run liquid adhesive with a surgical mesh patch, delivered through a single-handed applicator designed for controlled and precise placement. The company says the adhesive is engineered to create a strong bond while incorporating characteristics of silicone rubber, potentially providing greater flexibility and durability than conventional topical adhesives. The surgical mesh provides additional reinforcement, an important consideration for incision sites exposed to repeated mechanical stress, including those encountered in orthopaedic foot and ankle surgery. The system also forms a protective microbial barrier over the incision and is designed to support wound closure without requiring additional dressings. According to Resivant, the mesh can be removed without damaging surrounding skin, while the overall system is designed to minimize the potential for skin reactions and improve patient comfort. These features could make the technology applicable across multiple surgical specialties where reliable and flexible wound closure is required.

Clinical Expansion Supports Commercialization Plans

Following the first human use of Cutiva PLUS, additional clinical sites are onboarding the technology, with expanded clinical experience and further case results expected in the coming months. Resivant is continuing preparations for broader commercialization while investing in production capacity to support potential market expansion. The company’s adhesive technology originated from foundational research conducted at the University of Akron and is protected by a growing intellectual property portfolio. The first patient cases provide an important real-world milestone as the company transitions its proprietary adhesive chemistry from development and commercial-scale manufacturing toward wider clinical experience. The development of advanced wound-closure technologies is an important area within medical device innovation, particularly as surgeons seek products that can provide reliable closure while supporting flexibility, patient comfort and efficient application. Cutiva PLUS’s combination of adhesive and mesh reinforcement represents a differentiated approach to topical surgical wound closure, with the potential to support procedures across a range of specialties as clinical experience expands. Resivant’s progress also highlights the continued evolution of surgical adhesives and medical-device technologies designed to improve wound management and patient outcomes.

Source: Resivant Medical press relese